What extra factors come into play when prescribing ADHD medication during pregnancy planning?

When ADHD medication is being prescribed to someone who is planning a pregnancy, the decision becomes a balance between the potential effects of medication on pregnancy and the consequences of leaving ADHD inadequately treated. It isn't automatically a case of “stop the medication.” Key additional factors include: o Which ADHD medicine it is. The pregnancy evidence differs considerably between methylphenidate, lisdexamfetamine/dexamfetamine, atomoxetine, guanfacine, etc. For example, UKTIS/BUMPS currently says therapeutic amphetamines can be used in pregnancy when recommended by a specialist, and they are not known to cause birth defects, although later-pregnancy exposure may have implications for fetal growth and possibly pre-eclampsia. o How severe the ADHD is without treatment. If stopping medication causes major impairment—for example, difficulty functioning at work, driving safely, maintaining routines, or looking after oneself—the risks of untreated ADHD have to be considered alongside medication risks. o Whether the person is stable on their current treatment. Switching to a theoretically preferable medication can itself cause problems if it doesn't work or produces significant adverse effects. BUMPS specifically notes that someone whose condition is well controlled on methylphenidate may be better staying on it rather than changing and risking relapse. o Timing. The potential concerns aren't necessarily the same before conception, during the first trimester, and later in pregnancy. Later exposure can raise particular concerns about fetal growth and maternal blood pressure for stimulant medications. o Dose and formulation. The aim is generally the lowest effective dose rather than simply stopping treatment regardless of circumstances. o Maternal cardiovascular effects. Stimulants can increase blood pressure and heart rate, so baseline and ongoing monitoring becomes particularly relevant during pregnancy. NICE recommends monitoring pulse and blood pressure in people receiving ADHD medication. o Other medications and health conditions. Pregnancy planning is a good time to review the entire medication list, including drugs for anxiety/depression, migraine, sleep, blood pressure and other conditions, because interactions and pregnancy safety can change the overall calculation. o Non-medication strategies. Some people can reduce or pause medication with structured ADHD support, environmental adaptations, behavioural strategies and practical assistance; others cannot function adequately without medication. o The pregnancy itself. If conception occurs unexpectedly while taking ADHD medication, don't abruptly stop it without medical advice. BUMPS recommends discussing ongoing treatment with the GP/specialist promptly. o Pregnancy monitoring. Depending on the drug and circumstances, clinicians may pay particular attention to maternal blood pressure and fetal growth. For methylphenidate, BUMPS says routine extra anomaly monitoring isn't required, although additional growth scans may sometimes be offered later in pregnancy.